RxDoctor Payments Data

Joshua Trinidad, DO

Gynecologic Oncology · Winston Salem, NCNPI 1063771079

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Merck at 41.6% of the total. Reporting peaked in 2019 at $263 and has fallen 89.5% since, to $28 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in NC, where the typical reported total is $1,376.

$550in general payments, 2019–2025

Across 14 payments — averaging $39.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$229
  • Intuitive Surgical$106
  • Clovis Oncology, Inc.$95
  • Stryker$95
  • Eisai Inc.$14
  • Tesaro, Inc.$12
$802,947in research payments, 2019–2025

Across 54 payments — averaging $14,869 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$709K
  • Genentech, Inc.$58K
  • Pfizer$26K
  • AstraZeneca$10K

What the payments were for

  • Food & beverage$54599%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$550 in reported general payments places this provider in the 35th percentile of 52 gynecologic oncology providers in North Carolina.

See all gynecologic oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$65,880
Medicare patients
115
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$14,916
Prochlorperazine Maleate48$1,240
Gabapentin101$947
Clobetasol Propionate27$537
Norethindrone Acetate23$421
Ondansetron Hcl33$370
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$353
Dexamethasone15$293
Lidocaine-PrilocaineLidocaine/Prilocaine24$271
Venlafaxine Hcl ErVenlafaxine Hcl15$252
Letrozole20$224
Ibuprofen31$201
Oxycodone Hcl30$112
Fluconazole26$104
Promethazine Hcl34$65

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →